There is growing interest in the use of nontraditional short-term biomarkers of hyperglycemia [fructosamine, glycated albumin, and 1,5-anhydroglucitol (1,5-AG)]
1 to complement fasting glucose and hemoglobin A 1c (Hb A 1c ) for prognosis and management of diabetes (1 ) . Within-person variability in Hb A 1c and fasting glucose has been previously characterized (2) (3) (4) , but little is known about the variability of these alternative biomarkers of hyperglycemia in the general population. We quantified the 6-week total variability in fructosamine, glycated albumin, and 1,5-AG in older adults with and without diabetes and compared it to that of fasting glucose and Hb A 1c .
We included 153 participants from the Atherosclerosis Risk in Communities (ARIC) Study (5 ) who attended the initial visit-5 exam (2011-13), returned for a second visit scheduled 4 -8 weeks later, had complete data, fasted Ն8 h at both visits, and did not have outlying values. Institutional review boards approved all procedures, and all study participants provided written informed consent.
Serum fructosamine, glycated albumin, and 1,5-AG were measured with the Roche Cobas 6000 (Roche Diagnostics). Fructosamine was measured with a colorimetric method (Roche Diagnostics). Glycated albumin (Asahi Kasei Lucica GA-L) and 1, . We then calculated the index of individuality:
)/CV G or equivalently, CV W /CV G . We also calculated the intraclass correlation coefficient (ICC): BS 2 /( BS 2 ϩ WS 2 ). All statistical analyses were conducted with Stata, version 13.0 (StataCorp).
The mean age was 76 years, 33% had a diagnosis of diabetes, 39% were male, and 74% were white. The mean time between the original and second examinations was 45 days (SD, 16 days) (range 23-102 days). Estimates of total CV W for fructosamine, glycated albumin, and 1,5-AG were 3.4%, 2.7%, and 2.9%, respectively, in those without diabetes, and 3.7%, 3.8%, and 5.7% in those with diabetes (Table 1) . CV w values for fasting glucose and Hb A 1c were similar to those previously reported (Table 1 ) (2, 3 ) . The point estimates for the CV W values were greater in those with diagnosed diabetes-60% of whom reported taking glucoselowering medication-compared to those without diagnosed diabetes, although the CIs for fructosamine and glycated albumin in those with and without diabetes overlapped. The results in individuals with diabetes may partially reflect the influence of diabetes management on glycemic variability. The CV w values of fructosamine, glycated albumin, and 1,5-AG were between those of fasting glucose and Hb A 1c . Of the nontraditional biomarkers, the ICC was lowest for fructosamine and highest for 1,5-AG (Table 1). Patterns of Spearman rank correlation coefficients were similar to those of ICCs (Table 1 ). All biomarkers had a favorably low index of individuality, with 1,5-AG having the lowest (Table 1) . Results for Hb A 1c and fasting glucose were similar to previously reported findings (2-4) .
Estimates of total variability of these biomarkers were intermediate between fasting glucose and Hb A 1c , consistent with their biology (1 ) . Notably, 1,5-AG had very high correlations and estimates of reliability, which may be partially attributed to the relatively wide range of values for this biomarker. All biomarkers of hyperglycemia had a low index of individuality, which suggests that changes in biomarker levels over time within an individual primarily reflect biological change. Limitations of our study include havingonly2measurementsforeachpar-ticipant and the use of internal laboratory QC materials instead of duplicates to obtain the analytical CV.
In summary, we found that nontraditional biomarkers of hyperglycemia are consistent over approximately 6 weeks and have lower within-person variability than fasting glucose. These data should help inform the use of these biomarkers in research and clinical settings. 
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